This entry has been replaced by an amended Lobbying Activity Report:
1774-52855
|
Organization:
|
Innovative Medicines Canada (Medicaments novateurs Canada)
|
|
Associated registration:
|
10310-1774-72
|
|
Lobbying Activity date:
|
2026-04-15
|
|
Arranged a meeting:
|
Yes
|
|
Posted date:
|
2026-05-14
|
| In-house lobbyists who participated in the lobbying activity: |
Bettina Hamelin
|
|
Senior Public Office Holders who were lobbied in this activity:
|
Tijana Fazlagic,
Executive Director
Therapeutic Assessment & Access Branch at BC,
Health
|
| |
Subject Matter of the Lobbying Activity
|
Specific Topics of Lobbying Communications
|
Intended Outcomes
|
Associated Subject Matters
|
Policy measures to ensure security of drug supply in Canada and preserve Canada’s attractiveness for biopharmaceutical launches, including in response to foreign pricing regulations and their impact on patient access and economic growth in British Colombia
|
- Development, establishment, amendment or termination of any program, policy, directive or guideline of the government of British Columbia or a Provincial entity
|
Economic Development and Trade, Health, Intellectual Property, International Relations, International Trade, Science and Technology
|
|
| |
|
Lobbying Activity Report replaced on:
|
2026-07-13
amended entry:
1774-52855
|
| |
|
Senior officer who filed this Lobbying Activity Report:
|
Bettina Hamelin
|
| |
|
The above name is that of the most senior paid officer who is responsible for filing a Lobbying Activity Report for the organization (the Designated Filer), whether that person participated in this lobbying activity or not.
|